Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Aimmune

This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.

EU authorises Aimmune’s peanut allergy treatment Palforzia

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation. Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. ... Aimmune’s potential rival, DBV Technologies, has not had

Latest news

  • Nestlé is set to acquire Aimmune in deal worth $2.6bn Nestlé is set to acquire Aimmune in deal worth $2.6bn

    Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug. Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after ... Aimmune’s launch of Palforzia has been hampered by

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... Every month of delay gives Aimmune more time to extend its

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    Aimmune has also filed for approval in Europe, with a verdict due later this year. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major world markets could be worth $4.5bn in 2027, with Aimmune claiming a

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Aimmune has also been filed for approval in Europe, with a

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee

More from news
Approximately 9 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia